Z-213
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Iron Deficiency Anemia
Conditions
Iron Deficiency Anemia
Trial Timeline
Jul 1, 2016 → Dec 1, 2017
NCT ID
NCT02828319About Z-213
Z-213 is a phase 3 stage product being developed by Zeria Pharmaceutical for Iron Deficiency Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT02828319. Target conditions include Iron Deficiency Anemia.
What happened to similar drugs?
5 of 12 similar drugs in Iron Deficiency Anemia were approved
Approved (5) Terminated (0) Active (7)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02828319 | Phase 3 | Completed |
| NCT02170311 | Phase 1 | Completed |
Competing Products
20 competing products in Iron Deficiency Anemia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| KER-047 | Keros Therapeutics | Phase 2 | 17 |
| H. pylori treatment | Eisai | Phase 2/3 | 38 |
| Deferasirox | Novartis | Phase 3 | 40 |
| CSJ137 + Placebo | Novartis | Phase 1 | 29 |
| Deferasirox and Deferoxamine | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 2 | 35 |
| ICL670 | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Deferasirox + Deferasirox | Novartis | Phase 2/3 | 38 |
| Desferasirox | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Deferasirox dispersible tablet + Defearisox film-coated tablet | Novartis | Phase 2 | 35 |
| deferasirox | Novartis | Approved | 43 |
| Deferasirox (ICL670) | Novartis | Phase 1/2 | 32 |
| ICL670 | Novartis | Approved | 43 |
| Deferasirox | Novartis | Phase 3 | 40 |
| Core Study: Deferasirox + Core Study: Deferoxamine + Extension: deferoxamine to deferasirox + Extension: deferasirox to deferoxamine + Deferasirox + Deferoxamine | Novartis | Phase 2 | 35 |
| Deferasirox | Novartis | Approved | 43 |
| Z-213 + Saccharated Ferric Oxide | Zeria Pharmaceutical | Phase 3 | 40 |